- Home
- RVSB vs CGTX Comparison
RVSB vs CGTX Comparison
Compare RVSB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSB | CGTX |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.9M | 94.5M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RVSB | CGTX |
|---|---|---|
| Price | $5.22 | $1.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $3.33 |
| AVG Volume (30 Days) | 42.1K | ★ 584.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $9.82 | N/A |
| P/E Ratio | $29.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $0.22 |
| 52 Week High | $6.59 | $3.83 |
Technical Indicators
Market Signals| Indicator | RVSB | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 47.49 |
| Support Level | $4.81 | $1.00 |
| Resistance Level | $5.45 | $1.19 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 34.18 | 52.78 |
Price Performance
Historical ComparisonAbout RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.